Last call for nominations on notable women in biopharma

Over the last few weeks we've gathered dozens of excellent nominations for our annual issue on the most notable women in biopharma. And I wanted to offer up one last chance for readers to submit a name before we close the books and make the final selection.

Like most of our annual specials, this report is based on the life sciences team's work over the past year. As women have risen steadily in the ranks on both the science side and the business end of drug development, they are increasingly in line for top jobs in the industry. And they are making headlines.

They are also blazing a path that will be followed by a new generation of biopharma leaders. 

This is our third special report on women in the industry. With your help, we hope to make it the best one to date. So if you know someone who should be highlighted--and hasn't been on the list before--get your nomination in by COB next Friday. 

Here's the survey >>

As a handy guide to the qualities we're looking for, here's a look at past winners. -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.

  • FierceBiotech's 2010 Women in Biotech
  • FierceBiotech's 2011 Women in Biotech

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.